

## HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information for COTELLIC.

**COTELLIC (cobimetinib) tablets, for oral use**  
**Initial U.S. Approval: 2015**

### INDICATIONS AND USAGE

COTELLIC is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. (1, 14)

**Limitation of Use:** COTELLIC is not indicated for treatment of patients with wild-type BRAF melanoma.

### DOSAGE AND ADMINISTRATION

- Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to initiation of COTELLIC. (2.1)
- The recommended dose is 60 mg orally once daily for the first 21 days of each 28-day cycle until disease progression or unacceptable toxicity. Take COTELLIC with or without food. (2.2)

### DOSAGE FORMS AND STRENGTHS

Tablets: 20 mg (3)

### CONTRAINDICATIONS

None. (4)

### WARNINGS AND PRECAUTIONS

- **New primary malignancies, cutaneous and non-cutaneous:** Monitor patients for new malignancies prior to initiation of therapy, while on therapy, and for up to 6 months following the last dose of COTELLIC. (5.1)
- **Hemorrhage:** Major hemorrhagic events can occur with COTELLIC. Monitor for signs and symptoms of bleeding. (5.2, 2.4)
- **Cardiomyopathy:** The risk of cardiomyopathy is increased in patients receiving COTELLIC with vemurafenib compared with vemurafenib as a single agent. The safety of COTELLIC has not been established in patients

with decreased left ventricular ejection fraction (LVEF). Evaluate LVEF before treatment, after one month of treatment, then every 3 months thereafter during treatment with COTELLIC. (5.3, 2.4)

- **Severe Dermatologic Reactions:** Monitor for severe skin rashes. Interrupt, reduce, or discontinue COTELLIC. (5.4, 2.4)
- **Serous Retinopathy and Retinal Vein Occlusion:** Perform an ophthalmological evaluation at regular intervals and for any visual disturbances. Permanently discontinue COTELLIC for retinal vein occlusion (RVO). (5.5, 2.4)
- **Hepatotoxicity:** Monitor liver laboratory tests during treatment and as clinically indicated. (5.6, 2.4)
- **Rhabdomyolysis:** Monitor creatine phosphokinase periodically and as clinically indicated for signs and symptoms of rhabdomyolysis. (5.7, 2.4)
- **Severe Photosensitivity:** Advise patients to avoid sun exposure. (5.8, 2.4)
- **Embryo-Fetal Toxicity:** Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. (5.9, 8.1, 8.3)

### ADVERSE REACTIONS

Most common adverse reactions for COTELLIC ( $\geq 20\%$ ) are diarrhea, photosensitivity reaction, nausea, pyrexia, and vomiting. The most common ( $\geq 5\%$ ) Grade 3-4 laboratory abnormalities are increased GGT, increased CPK, hypophosphatemia, increased ALT, lymphopenia, increased AST, increased alkaline phosphatase, hyponatremia. (6.1)

**To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

### DRUG INTERACTIONS

Avoid concomitant administration of COTELLIC with strong or moderate CYP3A inducers or inhibitors. (2.3, 7.1, 7.2)

### USE IN SPECIFIC POPULATIONS

Lactation: Do not breastfeed while taking COTELLIC. (8.2)

**See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.**

**Revised: 11/2015**

## FULL PRESCRIBING INFORMATION: CONTENTS\*

### 1 INDICATIONS AND USAGE

### 2 DOSAGE AND ADMINISTRATION

- 2.1 Patient Selection
- 2.2 Recommended Dose
- 2.3 Dose Modification for Concurrent CYP3A Inhibitors
- 2.4 Dose Modifications

### 3 DOSAGE FORMS AND STRENGTHS

### 4 CONTRAINDICATIONS

### 5 WARNINGS AND PRECAUTIONS

- 5.1 New Primary Malignancies
- 5.2 Hemorrhage
- 5.3 Cardiomyopathy
- 5.4 Severe Dermatologic Reactions
- 5.5 Serous Retinopathy and Retinal Vein Occlusion
- 5.6 Hepatotoxicity
- 5.7 Rhabdomyolysis
- 5.8 Severe Photosensitivity
- 5.9 Embryo-Fetal Toxicity

### 6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience

### 7 DRUG INTERACTIONS

- 7.1 Effect of Strong or Moderate CYP3A4 Inhibitors on Cobimetinib
- 7.2 Effect of Strong or Moderate CYP3A Inducers on Cobimetinib

### 8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.3 Females and Males of Reproductive Potential
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Hepatic Impairment
- 8.7 Renal Impairment

### 10 OVERDOSAGE

### 11 DESCRIPTION

### 12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

### 13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

### 14 CLINICAL STUDIES

### 16 HOW SUPPLIED/STORAGE AND HANDLING

### 17 PATIENT COUNSELING INFORMATION

\*Sections or subsections omitted from the full prescribing information are not listed

1 **FULL PRESCRIBING INFORMATION**

2 **1 INDICATIONS AND USAGE**

3 COTELLIC is indicated for the treatment of patients with unresectable or metastatic melanoma with a  
4 BRAF V600E or V600K mutation, in combination with vemurafenib.

5 **Limitation of Use:** COTELLIC is not indicated for treatment of patients with wild-type BRAF melanoma  
6 [see *Warnings and Precautions (5)*].

7 **2 DOSAGE AND ADMINISTRATION**

8 **2.1 Patient Selection**

9 Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to initiation of  
10 treatment with COTELLIC with vemurafenib. Information on FDA-approved tests for the detection of  
11 BRAF V600 mutations in melanoma is available at: <http://www.fda.gov/CompanionDiagnostics>.

12 **2.2 Recommended Dose**

13 The recommended dosage regimen of COTELLIC is 60 mg (three 20 mg tablets) orally taken once daily for  
14 the first 21 days of each 28-day cycle until disease progression or unacceptable toxicity [see *Clinical Studies*  
15 (14)].

16 Take COTELLIC with or without food [see *Clinical Pharmacology (12.3)*].

17 If a dose of COTELLIC is missed or if vomiting occurs when the dose is taken, resume dosing with the next  
18 scheduled dose.

19 **2.3 Dose Modification for Concurrent CYP3A Inhibitors**

20 Do not take strong or moderate CYP3A inhibitors while taking COTELLIC.

21 If concurrent short term (14 days or less) use of moderate CYP3A inhibitors is unavoidable for patients who  
22 are taking COTELLIC 60 mg, reduce COTELLIC dose to 20 mg. After discontinuation of a moderate  
23 CYP3A inhibitor, resume previous dose of COTELLIC 60 mg [see *Drug Interactions (7.1) and Clinical*  
24 *Pharmacology (12.3)*].

25 Use an alternative to a strong or moderate CYP3A inhibitor in patients who are taking a reduced dose of  
26 COTELLIC (40 or 20 mg daily) [see *Drug Interactions (7.1) and Clinical Pharmacology (12.3)*].

27 **2.4 Dose Modifications**

28 Review the Full Prescribing Information for vemurafenib for recommended dose modifications.

29 **Table 1. Recommended Dose Reductions for COTELLIC**

First Dose Reduction	40 mg orally once daily
Second Dose Reduction	20 mg orally once daily
Subsequent Modification	Permanently discontinue COTELLIC if unable to tolerate 20 mg orally once daily

30 **Table 2. Recommended Dose Modifications for COTELLIC for Adverse Reactions**

Severity of Adverse Reaction <sup>a</sup>	Dose Modification for COTELLIC
<i>New Primary Malignancies (cutaneous and non-cutaneous)</i>	No dose modification is required.
<i>Hemorrhage</i>	
Grade 3	Withhold COTELLIC for up to 4 weeks. <ul style="list-style-type: none"> <li>• If improved to Grade 0 or 1, resume at the next lower dose level.</li> <li>• If not improved within 4 weeks, permanently discontinue.</li> </ul>
Grade 4	Permanently discontinue.
<i>Cardiomyopathy</i>	
Asymptomatic, absolute decrease in LVEF from baseline of greater than 10% <u>and</u> less than institutional lower limit of normal (LLN)	Withhold COTELLIC for 2 weeks; repeat LVEF.  Resume at next lower dose if <u>all</u> of the following are present <ul style="list-style-type: none"> <li>• LVEF is at or above LLN <u>and</u></li> <li>• Absolute decrease from baseline LVEF is 10% or less.</li> </ul> Permanently discontinue if <u>any</u> of the following are present <ul style="list-style-type: none"> <li>• LVEF is less than LLN <u>or</u></li> <li>• Absolute decrease from baseline LVEF is more than 10%.</li> </ul>
Symptomatic LVEF decrease from baseline	Withhold COTELLIC for up to 4 weeks, repeat LVEF.  Resume at next lower dose if <u>all</u> of the following are present: <ul style="list-style-type: none"> <li>• Symptoms resolve <u>and</u></li> <li>• LVEF is at or above LLN <u>and</u></li> <li>• Absolute decrease from baseline LVEF is 10% or less.</li> </ul> Permanently discontinue if <u>any</u> of the following are present <ul style="list-style-type: none"> <li>• Symptoms persist, <u>or</u></li> <li>• LVEF is less than LLN, <u>or</u></li> <li>• Absolute decrease from baseline LVEF is more than 10%.</li> </ul>
<i>Dermatologic Reactions</i>	
Grade 2 (intolerable), Grade 3 or 4	Withhold or reduce dose.
<i>Serous Retinopathy or Retinal Vein Occlusion</i>	
Serous retinopathy	Withhold COTELLIC for up to 4 weeks. <ul style="list-style-type: none"> <li>• If signs and symptoms improve, resume at the next lower dose level.</li> <li>• If not improved or symptoms recur at the lower dose within 4 weeks, permanently discontinue.</li> </ul>
Retinal vein occlusion	Permanently discontinue COTELLIC.

Severity of Adverse Reaction <sup>a</sup>	Dose Modification for COTELLIC
<i>Liver Laboratory Abnormalities and Hepatotoxicity</i>	
First Occurrence Grade 4	Withhold COTELLIC for up to 4 weeks. <ul style="list-style-type: none"> <li>• If improved to Grade 0 or 1, then resume at the next lower dose level.</li> <li>• If not improved to Grade 0 or 1 within 4 weeks, permanently discontinue.</li> </ul>
Recurrent Grade 4	Permanently discontinue COTELLIC.
<i>Rhabdomyolysis and Creatine Phosphokinase (CPK) elevations</i>	
<ul style="list-style-type: none"> <li>• Grade 4 CPK elevation</li> <li>• Any CPK elevation and myalgia</li> </ul>	Withhold COTELLIC for up to 4 weeks. <ul style="list-style-type: none"> <li>• If improved to Grade 3 or lower, resume at the next lower dose level.</li> <li>• If not improved within 4 weeks, permanently discontinue.</li> </ul>
<i>Photosensitivity</i>	
Grade 2 (intolerable), Grade 3 or Grade 4	Withhold COTELLIC for up to 4 weeks. <ul style="list-style-type: none"> <li>• If improved to Grade 0 or 1, resume at the next lower dose level.</li> <li>• If not improved within 4 weeks, permanently discontinue.</li> </ul>
<i>Other</i>	
<ul style="list-style-type: none"> <li>• Grade 2 (intolerable) adverse reactions</li> <li>• Any Grade 3 adverse reactions</li> </ul>	Withhold COTELLIC for up to 4 weeks. <ul style="list-style-type: none"> <li>• If improved to Grade 0 or 1, resume at the next lower dose level.</li> <li>• If not improved within 4 weeks, permanently discontinue.</li> </ul>
First occurrence of any Grade 4 adverse reaction	<ul style="list-style-type: none"> <li>• Withhold COTELLIC until adverse reaction improves to Grade 0 or 1. Then resume at the next lower dose level, <i>OR</i></li> <li>• Permanently discontinue.</li> </ul>
Recurrent Grade 4 adverse reaction	Permanently discontinue COTELLIC.

31 <sup>a</sup> National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0)

32 **3 DOSAGE FORMS AND STRENGTHS**

33 Tablets: 20 mg, white, round, film-coated, debossed on one side with “COB”.

34 **4 CONTRAINDICATIONS**

35 None.

36 **5 WARNINGS AND PRECAUTIONS**

37 Review the Full Prescribing Information for vemurafenib for information on the serious risks of  
38 vemurafenib.

39 **5.1 New Primary Malignancies**

40 New primary malignancies, cutaneous and non-cutaneous, can occur with COTELLIC.

41 Cutaneous Malignancies:

42 In Trial 1, the following cutaneous malignancies or premalignant conditions occurred in the COTELLIC  
43 with vemurafenib arm and the vemurafenib arm, respectively: cutaneous squamous cell carcinoma (cuSCC)  
44 or keratoacanthoma (KA) (6% and 20%), basal cell carcinoma (4.5% and 2.4%), and second primary  
45 melanoma (0.8% and 2.4%). Among patients receiving COTELLIC with vemurafenib, the median time to  
46 detection of first cuSCC/KA was 4 months (range: 2 to 11 months), and the median time to detection of  
47 basal cell carcinoma was 4 months (range: 27 days to 13 months). The time to onset in the two patients with  
48 second primary melanoma was 9 months and 12 months.

49 Perform dermatologic evaluations prior to initiation of therapy and every 2 months while on therapy.  
50 Manage suspicious skin lesions with excision and dermatopathologic evaluation. No dose modifications are  
51 recommended for COTELLIC [see *Dosage and Administration (2.4)*]. Conduct dermatologic monitoring for  
52 6 months following discontinuation of COTELLIC when administered with vemurafenib.

### 53 Non-Cutaneous Malignancies:

54 Based on its mechanism of action, vemurafenib may promote growth and development of malignancies  
55 [refer to the *Full Prescribing Information for vemurafenib*]. In Trial 1, 0.8% of patients in the COTELLIC  
56 with vemurafenib arm and 1.2% of patients in the vemurafenib arm developed non-cutaneous malignancies.

57 Monitor patients receiving COTELLIC, when administered with vemurafenib, for signs or symptoms of  
58 non-cutaneous malignancies.

## 59 **5.2 Hemorrhage**

60 Hemorrhage, including major hemorrhages defined as symptomatic bleeding in a critical area or organ, can  
61 occur with COTELLIC.

62 In Trial 1, the incidence of Grade 3–4 hemorrhages was 1.2% in patients receiving COTELLIC with  
63 vemurafenib and 0.8% in patients receiving vemurafenib. Hemorrhage (all grades) was 13% in patients  
64 receiving COTELLIC with vemurafenib and 7% in patients receiving vemurafenib. Cerebral hemorrhage  
65 occurred in 0.8% of patients receiving COTELLIC with vemurafenib and in none of the patients receiving  
66 vemurafenib. Gastrointestinal tract hemorrhage (3.6% vs 1.2%), reproductive system hemorrhage (2.0% vs  
67 0.4%), and hematuria (2.4% vs 0.8%) also occurred at a higher incidence in patients receiving COTELLIC  
68 with vemurafenib compared with patients receiving vemurafenib.

69 Withhold COTELLIC for Grade 3 hemorrhagic events. If improved to Grade 0 or 1 within 4 weeks, resume  
70 COTELLIC at a lower dose level. Discontinue COTELLIC for Grade 4 hemorrhagic events and any Grade  
71 3 hemorrhagic events that do not improve [see *Dosage and Administration (2.4)*].

## 72 **5.3 Cardiomyopathy**

73 Cardiomyopathy, defined as symptomatic and asymptomatic decline in left ventricular ejection fraction  
74 (LVEF), can occur with COTELLIC. The safety of COTELLIC has not been established in patients with a  
75 baseline LVEF that is either below institutional lower limit of normal (LLN) or below 50%.

76 In Trial 1, patients were assessed for decreases in LVEF by echocardiograms or MUGA at baseline, Week  
77 5, Week 17, Week 29, Week 43, and then every 4 to 6 months thereafter while receiving treatment. Grade 2  
78 or 3 decrease in LVEF occurred in 26% of patients receiving COTELLIC with vemurafenib and 19% of  
79 patients receiving vemurafenib. The median time to first onset of LVEF decrease was 4 months (range 23  
80 days to 13 months). Of the patients with decreased LVEF, 22% had dose interruption and/or reduction and  
81 14% required permanent discontinuation. Decreased LVEF resolved to above the LLN or within 10% of  
82 baseline in 62% of patients receiving COTELLIC with a median time to resolution of 3 months (range: 4  
83 days to 12 months).

84 Evaluate LVEF prior to initiation, 1 month after initiation, and every 3 months thereafter until  
85 discontinuation of COTELLIC. Manage events of left ventricular dysfunction through treatment  
86 interruption, reduction, or discontinuation [see *Dosage and Administration (2.4)*]. In patients restarting  
87 COTELLIC after a dose reduction or interruption, evaluate LVEF at approximately 2 weeks, 4 weeks, 10  
88 weeks, and 16 weeks, and then as clinically indicated.

## 89 **5.4 Severe Dermatologic Reactions**

90 Severe rash and other skin reactions can occur with COTELLIC.

91 In Trial 1, Grade 3 to 4 rash, occurred in 16% of patients receiving COTELLIC with vemurafenib and in  
92 17% of patients receiving vemurafenib, including Grade 4 rash in 1.6% of patients receiving COTELLIC  
93 with vemurafenib and 0.8% of the patients receiving vemurafenib. The incidence of rash resulting in

94 hospitalization was 3.2% in patients receiving COTELLIC with vemurafenib and 2.0% in patients receiving  
95 vemurafenib. In patients receiving COTELLIC, the median time to onset of Grade 3 or 4 rash events was 11  
96 days (range: 3 days to 2.8 months). Among patients with Grade 3 or 4 rash events, 95% experienced  
97 complete resolution with the median time to resolution of 21 days (range 4 days to 17 months).

98 Interrupt, reduce the dose, or discontinue COTELLIC [*see Dosage and Administration (2.4)*].

## 99 **5.5 Serous Retinopathy and Retinal Vein Occlusion**

100 Ocular toxicities can occur with COTELLIC, including serous retinopathy (fluid accumulation under layers  
101 of the retina).

102 In Trial 1, ophthalmologic examinations including retinal evaluation were performed pretreatment and at  
103 regular intervals during treatment. Symptomatic and asymptomatic serous retinopathy was identified in 26%  
104 of patients receiving COTELLIC with vemurafenib. The majority of these events were reported as  
105 chorioretinopathy (13%) or retinal detachment (12%). The time to first onset of serous retinopathy events  
106 ranged between 2 days to 9 months. The reported duration of serous retinopathy ranged between 1 day to 15  
107 months. One patient in each arm developed retinal vein occlusion.

108 Perform an ophthalmological evaluation at regular intervals and any time a patient reports new or worsening  
109 visual disturbances. If serous retinopathy is diagnosed, interrupt COTELLIC until visual symptoms improve.  
110 Manage serous retinopathy with treatment interruption, dose reduction, or with treatment discontinuation  
111 [*see Dosage and Administration (2.4)*].

## 112 **5.6 Hepatotoxicity**

113 Hepatotoxicity can occur with COTELLIC.

114 The incidences of Grade 3 or 4 liver laboratory abnormalities in Trial 1 among patients receiving  
115 COTELLIC with vemurafenib compared to patients receiving vemurafenib were: 11% vs. 6% for alanine  
116 aminotransferase, 7% vs. 2.1% for aspartate aminotransferase, 1.6% vs. 1.2% for total bilirubin, and 7% vs.  
117 3.3% for alkaline phosphatase [*see Adverse Drug Reactions (6.1)*]. Concurrent elevation in ALT >3 times  
118 the upper limit of normal (ULN) and bilirubin >2 X ULN in the absence of significant alkaline phosphatase  
119 >2 X ULN occurred in one patient (0.4%) receiving COTELLIC with vemurafenib and no patients receiving  
120 single-agent vemurafenib.

121 Monitor liver laboratory tests before initiation of COTELLIC and monthly during treatment, or more  
122 frequently as clinically indicated. Manage Grade 3 and 4 liver laboratory abnormalities with dose  
123 interruption, reduction, or discontinuation of COTELLIC [*see Dosage and Administration (2.4)*].

## 124 **5.7 Rhabdomyolysis**

125 Rhabdomyolysis can occur with COTELLIC.

126 In Trial 1, Grade 3 or 4 CPK elevations, including asymptomatic elevations over baseline, occurred in 12%  
127 of patients receiving COTELLIC with vemurafenib and 0.4% of patients receiving vemurafenib. The  
128 median time to first occurrence of Grade 3 or 4 CPK elevations was 16 days (range: 12 days to 11 months)  
129 in patients receiving COTELLIC with vemurafenib; the median time to complete resolution was 15 days  
130 (range: 9 days to 11 months). Elevation of serum CPK increase of more than 10 times the baseline value  
131 with a concurrent increase in serum creatinine of 1.5 times or greater compared to baseline occurred in 3.6%  
132 of patients receiving COTELLIC with vemurafenib and in 0.4% of patients receiving vemurafenib.

133 Obtain baseline serum CPK and creatinine levels prior to initiating COTELLIC, periodically during  
134 treatment, and as clinically indicated. If CPK is elevated, evaluate for signs and symptoms of  
135 rhabdomyolysis or other causes. Depending on the severity of symptoms or CPK elevation, dose  
136 interruption or discontinuation of COTELLIC may be required [*see Dosage and Administration (2.4)*].

## 137 **5.8 Severe Photosensitivity**

138 Photosensitivity, including severe cases, can occur with COTELLIC.

139 In Trial 1, photosensitivity was reported in 47% of patients receiving COTELLIC with vemurafenib: 43% of  
140 patients with Grades 1 or 2 photosensitivity and the remaining 4% with Grade 3 photosensitivity. Median  
141 time to first onset of photosensitivity of any grade was 2 months (range: 1 day to 14 months) in patients  
142 receiving COTELLIC with vemurafenib, and the median duration of photosensitivity was 3 months (range:  
143 2 days to 14 months). Among the 47% of patients with photosensitivity reactions on COTELLIC with  
144 vemurafenib, 63% experienced resolution of photosensitivity reactions.

145 Advise patients to avoid sun exposure, wear protective clothing and use a broad-spectrum UVA/UVB  
146 sunscreen and lip balm (SPF  $\geq$ 30) when outdoors. Manage intolerable Grade 2 or greater photosensitivity  
147 with dose modifications [*see Dosage and Administration (2.4)*].

## 148 **5.9 Embryo-Fetal Toxicity**

149 Based on its mechanism of action and findings from animal reproduction studies, COTELLIC can cause  
150 fetal harm when administered to a pregnant woman. In animal reproduction studies, oral administration of  
151 cobimetinib in pregnant rats during the period of organogenesis was teratogenic and embryotoxic at doses  
152 resulting in exposures [area under the curves (AUCs)] that were 0.9 to 1.4-times those observed in humans  
153 at the recommended human dose of 60 mg. Advise pregnant women of the potential risk to a fetus. Advise  
154 females of reproductive potential to use effective contraception during treatment with COTELLIC, and for 2  
155 weeks following the final dose of COTELLIC [*see Use in Specific Populations (8.1, 8.3), Clinical*  
156 *Pharmacology (12.1)*].

## 157 **6 ADVERSE REACTIONS**

158 The following adverse reactions are discussed in greater detail in other sections of the label:

- 159 • New Primary Cutaneous Malignancies [*see Warnings and Precautions (5.1)*]
- 160 • Hemorrhage [*see Warnings and Precautions (5.2)*]
- 161 • Cardiomyopathy [*see Warnings and Precautions (5.3)*]
- 162 • Serious Dermatologic Reactions [*see Warnings and Precautions (5.4)*]
- 163 • Serous Retinopathy and Retinal Vein Occlusion [*see Warnings and Precautions (5.5)*]
- 164 • Hepatotoxicity [*see Warnings and Precautions (5.6)*]
- 165 • Rhabdomyolysis [*see Warnings and Precautions (5.7)*]
- 166 • Severe Photosensitivity [*see Warnings and Precautions (5.8)*]
- 167 • Embryo-fetal Toxicity [*see Warnings and Precautions (5.9)*]

### 168 **6.1 Clinical Trials Experience**

169 Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the  
170 clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not  
171 reflect the rates observed in practice.

172 The safety of COTELLIC was evaluated in Trial 1, a randomized (1:1), double-blind, active-controlled trial  
173 in previously untreated patients with BRAF V600 mutation-positive, unresectable or metastatic melanoma  
174 [*see Clinical Studies (14)*]. All patients received vemurafenib 960 mg twice daily on Days 1–28 and  
175 received either COTELLIC 60 mg once daily (n=247) or placebo (n=246) on Days 1–21 of each 28-day  
176 treatment cycle until disease progression or unacceptable toxicity. In the COTELLIC plus vemurafenib arm,  
177 66% percent of patients were exposed for greater than 6 months and 24% of patients were exposed for  
178 greater than 1 year. Patients with abnormal liver function tests, history of acute coronary syndrome within 6  
179 months, evidence of Class II or greater congestive heart failure (New York Heart Association), active  
180 central nervous system lesions, or evidence of retinal pathology were excluded from Trial 1. The

181 demographics and baseline tumor characteristics of patients enrolled in Trial 1 are summarized in Clinical  
182 Studies [see *Clinical Studies (14)*].

183 In Trial 1, 15% of patients receiving COTELLIC experienced an adverse reaction that resulted in permanent  
184 discontinuation of COTELLIC. The most common adverse reactions resulting in permanent discontinuation  
185 were liver laboratory abnormalities defined as increased aspartate aminotransferase (AST) (2.4%), increased  
186 gamma glutamyltransferase (GGT) (1.6%) and increased alanine aminotransferase (ALT) (1.6%); rash  
187 (1.6%); pyrexia (1.2%); and retinal detachment (2%). Among the 247 patients receiving COTELLIC,  
188 adverse reactions led to dose interruption or reductions in 55%. The most common reasons for dose  
189 interruptions or reductions of COTELLIC were rash (11%), diarrhea (9%), chorioretinopathy (7%), pyrexia  
190 (6%), vomiting (6%), nausea (5%), and increased creatine phosphokinase (CPK) (4.9%). The most common  
191 ( $\geq 20\%$ ) adverse reactions with COTELLIC were diarrhea, photosensitivity reaction, nausea, pyrexia, and  
192 vomiting.

193 **Table 3. Incidence of Adverse Drug Reactions Occurring in  $\geq 10\%$  (All Grades) of Patients**  
194 **Receiving COTELLIC with Vemurafenib and at a Higher Incidence\* than Patients**  
195 **Receiving Vemurafenib in Trial 1**

Adverse reactions	COTELLIC + Vemurafenib (n=247)		Placebo + Vemurafenib (n=246)	
	All Grades <sup>a</sup> (%)	Grades 3–4 (%)	All Grades (%)	Grades 3–4 (%)
<b>GASTROINTESTINAL DISORDERS</b>				
Diarrhea	60	6	31	1
Nausea	41	1	25	1
Vomiting	24	1	13	1
Stomatitis <sup>b</sup>	14	1	8	0
<b>SKIN AND SUBCUTANEOUS TISSUE DISORDERS</b>				
Photosensitivity reaction <sup>c</sup>	46	4	35	0
Acneiform dermatitis	16	2	11	1
<b>GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS</b>				
Pyrexia	28	2	23	0
Chills	10	0	5	0
<b>VASCULAR DISORDERS</b>				
Hypertension	15	4	8	2
Hemorrhage <sup>d</sup>	13	1	7	<1
<b>EYE DISORDERS</b>				
Vision impaired <sup>e</sup>	15	<1	4	0
Chorioretinopathy	13	<1	<1	0
Retinal detachment <sup>f</sup>	12	2	<1	0

196 \*  $\geq 5\%$  for All Grades or  $\geq 2\%$  for Grades 3–4 incidence in patients receiving COTELLIC with vemurafenib compared with patients receiving  
197 vemurafenib as a single agent

198 <sup>a</sup> NCI CTCAE, v4.0.

199 <sup>b</sup> Includes stomatitis, aphthous stomatitis, mouth ulceration, and mucosal inflammation

200 <sup>c</sup> Includes solar dermatitis, sunburn, photosensitivity reaction

201 <sup>d</sup> Includes hemorrhage, rectal hemorrhage, melena, hemorrhoidal hemorrhage, gastrointestinal hemorrhage, hematemesis, hematochezia,  
202 gingival bleeding, metrorrhagia, uterine hemorrhage, hemorrhagic ovarian cyst, menometrorrhagia, menorrhagia, vaginal hemorrhage,  
203 hemoptysis, pulmonary, cerebral, subarachnoid hemorrhage, subgaleal hematoma, hematuria, epistaxis, contusion, traumatic hematoma,  
204 ecchymosis, purpura, nail bed bleeding, ocular, eye, conjunctival, and retinal hemorrhage

205 <sup>e</sup> Includes vision blurred, visual acuity reduced, visual impairment

206 <sup>f</sup> Includes retinal detachment, detachment of retinal pigment epithelium, detachment of macular retinal pigment epithelium

207

208 Adverse reactions of vemurafenib which occurred at a lower rate in patients receiving COTELLIC plus  
209 vemurafenib were alopecia (15%), hyperkeratosis (11%), and erythema (10%).



210 The following adverse reactions (all grades) of COTELLIC were reported with <10% incidence in Trial 1:

211 *Respiratory, thoracic and mediastinal disorders:* Pneumonitis

212 **Table 4. Incidence of Laboratory Abnormalities Occurring in ≥10% (All Grades) or ≥2%**  
213 **(Grades 3–4) of Patients in Trial 1\***

Laboratory	COTELLIC + Vemurafenib		Placebo + Vemurafenib	
	All Grades <sup>a</sup>	Grades 3–4 <sup>a</sup>	All Grades <sup>a</sup>	Grades 3–4 <sup>a</sup>
	%	%	%	%
<b>Chemistry</b>				
Increased creatinine	99.6	3.3	99.6	0.4
Increased AST	73	8	44	2.1
Increased ALT	68	11	55	5
Increased alkaline phosphatase	71	7	56	3.3
Increased creatine phosphokinase <sup>b</sup>	79	14	16	0.5
Hypophosphatemia	68	12	38	6
Increased GGT	65	21	61	17
Hyponatremia	38	6	33	2.1
Hypoalbuminemia	42	0.8	20	0.4
Hyopkalemia	25	4.5	17	3.3
Hyperkalemia	26	2.9	15	0.4
Hypocalcemia	24	0.4	10	1.7
<b>Hematology</b>				
Anemia	69	2.5	57	3.3
Lymphopenia <sup>c</sup>	73	10	55	8
Thrombocytopenia	18	0	10	0

214 AST - aspartate aminotransferase, ALT - alanine aminotransferase, GGT - gamma-glutamyltransferase

215 \*All the percentages are based on the number of patients who had a baseline result and at least one on-study laboratory test.  
216 The laboratory results are available for a total of 233~244 patients for COTELLIC, and 232~243 for vemurafenib, except  
217 where indicated.

218 <sup>a</sup>NCI CTCAE v4.0.

219 <sup>b</sup>Increase creatine phosphokinase, n=213 for COTELLIC and 217 for vemurafenib.

220 <sup>c</sup>Lymphopenia, n=185 for COTELLIC, and 181 for vemurafenib.

## 221 7 DRUG INTERACTIONS

### 222 7.1 Effect of Strong or Moderate CYP3A Inhibitors on Cobimetinib

223 Coadministration of COTELLIC with itraconazole (a strong CYP3A4 inhibitor) increased cobimetinib  
224 systemic exposure by 6.7-fold. Avoid concurrent use of COTELLIC and strong or moderate CYP3A  
225 inhibitors. If concurrent short term (14 days or less) use of moderate CYP3A inhibitors including certain  
226 antibiotics (e.g., erythromycin, ciprofloxacin) is unavoidable for patients who are taking COTELLIC 60 mg,  
227 reduce COTELLIC dose to 20 mg. After discontinuation of a moderate CYP3A inhibitor, resume  
228 COTELLIC at the previous dose [see *Dosage and Administration (2.3) and Clinical Pharmacology (12.3)*].  
229 Use an alternative to a strong or moderate CYP3A inhibitor in patients who are taking a reduced dose of  
230 COTELLIC (40 or 20 mg daily) [see *Dosage and Administration (2.3) and Clinical Pharmacology (12.3)*].

### 231 7.2 Effect of Strong or Moderate CYP3A Inducers on Cobimetinib

232 Coadministration of COTELLIC with a strong CYP3A inducer may decrease cobimetinib systemic  
233 exposure by more than 80% and reduce its efficacy. Avoid concurrent use of COTELLIC and strong or  
234 moderate CYP3A inducers including but not limited to carbamazepine, efavirenz, phenytoin, rifampin, and  
235 St. John's Wort [see *Clinical Pharmacology (12.3)*].

236 **8 USE IN SPECIFIC POPULATIONS**

237 **8.1 Pregnancy**

238 Risk Summary

239 Based on findings from animal reproduction studies and its mechanism of action, COTELLIC can cause  
240 fetal harm when administered to a pregnant woman [see *Clinical Pharmacology (12.1)*]. There are no  
241 available data on the use of COTELLIC during pregnancy. In animal reproduction studies, oral  
242 administration of cobimetinib in pregnant rats during organogenesis was teratogenic and embryotoxic at  
243 exposures (AUC) that were 0.9 to 1.4-times those observed in humans at the recommended human dose of  
244 60 mg [see *Data*]. Advise pregnant women of the potential risk to a fetus.

245 In the U.S. general population, the estimated background risk of major birth defects and miscarriage in  
246 clinically recognized pregnancies is 2–4% and 15–20%, respectively.

247 Data

248 *Animal Data*

249 Administration of cobimetinib to pregnant rats during the period of organogenesis resulted in increased  
250 post-implantation loss, including total litter loss, at exposures (AUC) of 0.9–1.4 times those in humans at  
251 the recommended dose of 60 mg. Post-implantation loss was primarily due to early resorptions. Fetal  
252 malformations of the great vessels and skull (eye sockets) occurred at the same exposures.

253 **8.2 Lactation**

254 Risk Summary

255 There is no information regarding the presence of cobimetinib in human milk, effects on the breastfed  
256 infant, or effects on milk production. Because of the potential for serious adverse reactions in a breastfed  
257 infant, advise a nursing woman not to breastfeed during treatment with COTELLIC and for 2 weeks after  
258 the final dose.

259 **8.3 Females and Males of Reproductive Potential**

260 Contraception

261 *Females*

262 COTELLIC can cause fetal harm when administered to a pregnant woman [see *Use in Specific Populations*  
263 (8.1)]. Advise females of reproductive potential to use effective contraception during treatment with  
264 COTELLIC and for 2 weeks after the final dose of COTELLIC.

265 Infertility

266 *Females and Males*

267 Based on findings in animals, COTELLIC may reduce fertility in females and males of reproductive  
268 potential [see *Nonclinical Toxicology (13.1)*].

269 **8.4 Pediatric Use**

270 The safety and effectiveness of COTELLIC have not been established in pediatric patients.

271 *Juvenile Animal Data*

272 In a 4-week juvenile rat toxicology study, daily oral doses of 3 mg/kg (approximately 0.13–0.5 times the  
273 adult human AUC at the recommended dose of 60 mg) between postnatal Days 10–17 (approximately  
274 equivalent to ages 1–2 years in humans) were associated with mortality, the cause of which was not defined.

275 **8.5 Geriatric Use**

276 Clinical studies of cobimetinib did not include sufficient numbers of patients aged 65 years and older to  
277 determine whether they respond differently from younger patients.

278 **8.6 Hepatic Impairment**

279 Pharmacokinetics of cobimetinib has not been studied in patients with moderate or severe hepatic  
280 impairment. Dose adjustment is not recommended for patients with mild hepatic impairment (total bilirubin  
281 less than or equal to ULN and AST greater than ULN **or** total bilirubin >ULN but  $\leq 1.5$  times ULN and any  
282 AST) based on results of the population pharmacokinetic analysis [see *Clinical Pharmacology (12.3)*].

283 **8.7 Renal Impairment**


284 No dedicated pharmacokinetic trial in patients with renal impairment has been conducted. Dose adjustment  
285 is not recommended for mild to moderate renal impairment (CLcr 30 to 89 mL/min) based on the results of  
286 the population pharmacokinetic analysis. A recommended dose has not been established for patients with  
287 severe renal impairment [see *Clinical Pharmacology (12.3)*].

288 **10 OVERDOSAGE**

289 There is no information on overdosage of COTELLIC.

290 **11 DESCRIPTION**

291 Cobimetinib fumarate is a kinase inhibitor. The chemical name is (S)-[3,4-difluoro-2-(2-fluoro-4-  
292 iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemifumarate. It has a  
293 molecular formula  $C_{46}H_{46}F_6I_2N_6O_8$  ( $2 C_{21}H_{21}F_3IN_3O_2 \cdot C_4H_4O_4$ ) with a molecular mass of 1178.71 as a  
294 fumarate salt. Cobimetinib fumarate has the following chemical structure:



295

296 Cobimetinib is a fumarate salt appearing as white to off-white solid and exhibits a pH dependent solubility.

297 COTELLIC (cobimetinib) tablets are supplied as white, round, film-coated 20 mg tablets for oral  
298 administration, debossed on one side with "COB". Each 20 mg tablet contains 22 mg of cobimetinib  
299 fumarate, which corresponds to 20 mg of the cobimetinib free base.

300 The inactive ingredients of COTELLIC are: **Tablet Core:** microcrystalline cellulose, lactose monohydrate,  
301 croscarmellose sodium, magnesium stearate. **Coating:** polyvinyl alcohol, titanium dioxide, polyethylene  
302 glycol 3350, talc.

303 **12 CLINICAL PHARMACOLOGY**

304 **12.1 Mechanism of Action**

305 Cobimetinib is a reversible inhibitor of mitogen-activated protein kinase (MAPK)/extracellular signal  
306 regulated kinase 1 (MEK1) and MEK2. MEK proteins are upstream regulators of the extracellular signal-  
307 related kinase (ERK) pathway, which promotes cellular proliferation. BRAF V600E and K mutations result  
308 in constitutive activation of the BRAF pathway which includes MEK1 and MEK2. In mice implanted with  
309 tumor cell lines expressing BRAF V600E, cobimetinib inhibited tumor cell growth.

310 Cobimetinib and vemurafenib target two different kinases in the RAS/RAF/MEK/ERK pathway. Compared  
311 to either drug alone, coadministration of cobimetinib and vemurafenib resulted in increased apoptosis in  
312 vitro and reduced tumor growth in mouse implantation models of tumor cell lines harboring BRAF V600E  
313 mutations. Cobimetinib also prevented vemurafenib-mediated growth enhancement of a wild-type BRAF  
314 tumor cell line in an in vivo mouse implantation model.

## 315 **12.2 Pharmacodynamics**

### 316 Cardiac Electrophysiology

317 Clinically relevant QT prolongation has been reported with vemurafenib, further QTc prolongation was not  
318 observed when cobimetinib 60 mg daily was co-administered with vemurafenib. Monitor ECG and  
319 electrolytes before initiating treatment and routinely during treatment with cobimetinib, when administered  
320 with vemurafenib. Review the Full Prescribing Information for vemurafenib for details.

## 321 **12.3 Pharmacokinetics**

322 The pharmacokinetics of cobimetinib was studied in healthy subjects and cancer patients. Cobimetinib  
323 exhibits linear pharmacokinetics in the dose range of 3.5 to 100 mg (i.e., 0.06 to 1.7 times the recommended  
324 dosage). Following oral administration of COTELLIC 60 mg once daily, steady-state was reached by 9 days  
325 with a mean accumulation ratio of 2.4-fold (44% CV).

### 326 Absorption

327 Following oral dosing of 60 mg once daily in cancer patients, the median time to achieve peak plasma levels  
328 ( $T_{max}$ ) was 2.4 (range: 1–24) hours, geometric mean steady-state  $AUC_{0-24h}$  was 4340 ng·h/mL (61% CV) and  
329  $C_{max}$  was 273 ng/mL (60% CV). The absolute bioavailability of COTELLIC was 46% (90% CI: 40%, 53%)  
330 in healthy subjects. A high-fat meal (comprised of approximately 150 calories from protein, 250 calories  
331 from carbohydrate, and 500–600 calories from fat) had no effect on cobimetinib AUC and  $C_{max}$  after a  
332 single 20 mg COTELLIC was administered to healthy subjects.

### 333 Distribution

334 Cobimetinib is 95% bound to human plasma proteins in vitro, independent of drug concentration. No  
335 preferential binding to human red blood cells was observed (blood to plasma ratio of 0.93). The estimated  
336 apparent volume of distribution was 806 L in cancer patients based on a population PK analysis.

### 337 Elimination

338 Following oral administration of COTELLIC 60 mg once daily in cancer patients, the mean elimination  
339 half-life ( $t_{1/2}$ ) was 44 (range: 23–70) hours and the mean apparent clearance (CL/F) was 13.8 L/h (61% CV).

### 340 *Metabolism*

341 CYP3A oxidation and UGT2B7 glucuronidation were the major pathways of cobimetinib metabolism in  
342 vitro. Following oral administration of a single 20 mg radiolabeled cobimetinib dose, no oxidative  
343 metabolites >10% of total circulating radioactivity were observed.

### 344 *Excretion*

345 Following oral administration of a single 20 mg radiolabeled cobimetinib dose, 76% of the dose was  
346 recovered in the feces (with 6.6% as unchanged drug) and 17.8% of the dose was recovered in the urine  
347 (with 1.6% as unchanged drug).

### 348 Specific Populations

349 *Age, Sex, and Race/Ethnicity:* Based on the population pharmacokinetic analysis, age (19–88 years), sex, or  
350 race/ethnicity does not have a clinically important effect on the systemic exposure of cobimetinib.

### 351 *Hepatic Impairment*

352 The pharmacokinetics of cobimetinib has not been studied in patients with moderate to severe hepatic  
353 impairment. As cobimetinib is metabolized and eliminated via the liver, patients with moderate to severe  
354 hepatic impairment may have increased exposure. Cobimetinib exposures were similar between 80 patients  
355 with mild hepatic impairment (total bilirubin  $\leq$  ULN and AST  $>$ ULN or total bilirubin  $>$ ULN but  $\leq$  1.5  
356 times ULN and any AST) and 388 patients with normal hepatic function (total bilirubin  $\leq$  ULN and AST  $\leq$   
357 ULN) [see Use in Specific Populations (8.6)].

#### 358 *Renal Impairment*

359 Cobimetinib undergoes minimal renal elimination. Cobimetinib exposures were similar in 151 patients with  
360 mild renal impairment (CLcr 60 to 89 mL/min), 48 patients with moderate renal impairment (CLcr 30 to 59  
361 mL/min) and 286 patients with normal renal function (CLcr  $\geq$ 90 mL/min) [see Use in Specific Populations  
362 (8.7)].

#### 363 Drug Interaction Studies

364 *Vemurafenib:* Coadministration of COTELLIC 60 mg once daily and vemurafenib 960 mg twice daily  
365 resulted in no clinically relevant pharmacokinetic drug interactions.

366 *Effect of Strong and Moderate CYP3A Inhibitors on Cobimetinib:* In vitro studies show that cobimetinib is a  
367 substrate of CYP3A. Coadministration of itraconazole (a strong CYP3A inhibitor) 200 mg once daily for 14  
368 days with a single 10 mg cobimetinib dose increased mean cobimetinib AUC (90% CI) by 6.7-fold (5.6,  
369 8.0) and mean  $C_{max}$  (90% CI) by 3.2-fold (2.7, 3.7) in 15 healthy subjects. Simulations showed that predicted  
370 steady-state concentrations of cobimetinib at a reduced dose of 20 mg administered concurrently with short-  
371 term (less than 14 days) treatment of a moderate CYP3A inhibitor were similar to observed steady-state  
372 concentrations of cobimetinib at the 60 mg dose alone [see Drug Interactions (7.1)].

373 *Effect of Strong and Moderate CYP3A Inducers on Cobimetinib:* Based on simulations, cobimetinib  
374 exposures would decrease by 83% when coadministered with a strong CYP3A inducer and by 73% when  
375 coadministered with a moderate CYP3A inducer [see Drug Interactions (7.2)].

376 *Effect of Cobimetinib on CYP Substrates:* Coadministration of cobimetinib 60 mg once daily for 15 days  
377 with a single 30 mg dose of dextromethorphan (sensitive CYP2D6 substrate) or a single 2 mg dose of  
378 midazolam (sensitive CYP3A substrate) to 20 patients with solid tumors did not change dextromethorphan  
379 or midazolam systemic exposure. In vitro data indicated that cobimetinib may inhibit CYP3A and CYP2D6.  
380 Cobimetinib at clinically relevant concentrations is not an inhibitor of CYP1A2, 2B6, 2C8, 2C9 and 2C19  
381 or inducer of CYP1A2, 2B6 and 3A4.

382 *Effect of Transporters on Cobimetinib:* Cobimetinib is a substrate of efflux transporter P-glycoprotein  
383 (P-gp), but is not a substrate of Breast Cancer Resistance Protein (BCRP), Organic Anion Transporting  
384 Polypeptide (OATP1B1 or OATP1B3) or Organic Cation Transporter (OCT1) in vitro. Drugs that inhibit  
385 P-gp may increase cobimetinib concentrations.

386 *Effect of Cobimetinib on Transporters:* In vitro data suggest that cobimetinib at clinically relevant  
387 concentrations does not inhibit P-gp, BCRP, OATP1B1, OATP1B3, or OCT1.

388 *Effect of Gastric Acid Reducing Drugs on Cobimetinib:* Coadministration of a proton pump inhibitor,  
389 rabeprazole 20 mg once daily for 5 days, with a single dose of 20 mg COTELLIC under fed and fasted  
390 conditions did not result in a clinically important change in cobimetinib exposure.

## 391 **13 NONCLINICAL TOXICOLOGY**

### 392 **13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

393 Carcinogenicity studies with cobimetinib have not been conducted. Cobimetinib was not genotoxic in  
394 studies evaluating reverse mutations in bacteria, chromosomal aberrations in mammalian cells, and  
395 micronuclei in bone marrow of rats.

396 No dedicated fertility studies have been performed with cobimetinib in animals; however, effects on  
397 reproductive tissues observed in general toxicology studies conducted in animals suggest that there is  
398 potential for cobimetinib to impair fertility. In female rats, degenerative changes included increased  
399 apoptosis/necrosis of corpora lutea and vaginal epithelial cells at cobimetinib doses approximately twice  
400 those in humans at the clinically recommended dose of 60 mg based on body surface area. In male dogs,  
401 testicular degeneration occurred at exposures as low as approximately 0.1 times the exposure in humans at  
402 the clinically recommended dose of 60 mg.

#### 403 **14 CLINICAL STUDIES**

404 The safety and efficacy of cobimetinib was established in a multicenter, randomized (1:1), double-blinded,  
405 placebo-controlled trial conducted in 495 patients with previously untreated, BRAF V600 mutation-positive,  
406 unresectable or metastatic, melanoma. The presence of BRAF V600 mutation was detected using the cobas<sup>®</sup>  
407 4800 BRAF V600 mutation test. All patients received vemurafenib 960 mg orally twice daily on days 1–28  
408 and were randomized to receive COTELLIC 60 mg or matching placebo orally once daily on days 1–21 of  
409 an every 28-day cycle. Randomization was stratified by geographic region (North America vs. Europe vs.  
410 Australia/New Zealand/others) and disease stage (unresectable Stage IIIc, M1a, or M1b vs. Stage M1c).  
411 Treatment continued until disease progression or unacceptable toxicity. Patients randomized to receive  
412 placebo were not offered COTELLIC at the time of disease progression.

413 The major efficacy outcome was investigator-assessed progression-free survival (PFS) per RECIST v1.1.  
414 Additional efficacy outcomes were investigator-assessed confirmed objective response rate, overall survival,  
415 PFS as assessed by blinded independent central review, and duration of response.

416 The median age of the study population was 55 years (range 23 to 88 years), 58% of patients were male,  
417 93% were White and 5% had no race reported, 60% had stage M1c disease, 72% had a baseline ECOG  
418 performance status of 0, 45% had an elevated baseline serum lactate dehydrogenase (LDH), 10% had  
419 received prior adjuvant therapy, and <1% had previously treated brain metastases. Patients with available  
420 tumor samples were retrospectively tested using next generation sequencing to further classify mutations as  
421 V600E or V600K; test results were obtained on 81% of randomized patients. Of these, 86% were identified  
422 as having a V600E mutation and 14% as having a V600K mutation.

423 Efficacy results are summarized in Table 5 and Figure 1.


424 **Table 5 Efficacy Results from Trial 1**

	<b>COTELLIC + Vemurafenib (n=247)</b>	<b>Placebo + Vemurafenib (n=248)</b>
<b>Progression-free Survival (Investigator-Assessed)</b>		
Number of Events (%)	143 (58%)	180 (73%)
Progression	131	169
Death	12	11
Median PFS, months (95% CI)	12.3 (9.5, 13.4)	7.2 (5.6,7.5)
Hazard Ratio (95% CI)	0.56 (0.45, 0.70)	
p-value (stratified log-rank test)	<0.001	
<b>Overall Survival</b>		
Number of Deaths (%)	79 (32%)	109 (44%)
Median OS, months (95% CI)	NE (20.7, NE)	17.0 (15.0, NE)
Hazard Ratio (95% CI)	0.63 (0.47, 0.85)	
p-value (stratified log-rank test)	0.0019 <sup>a</sup>	
<b>Objective Response Rate</b>		
Objective Response Rate	70%	50%
(95% CI)	(64%, 75%)	(44%, 56%)
Complete Response	16%	10%
Partial Response	54%	40%
P-value	<0.001	
Median Duration of Response, months (95% CI)	13.0 (11.1, 16.6)	9.2 (7.5, 12.8)

425 CI - Confidence Intervals; NE - not estimable

426 <sup>a</sup>Statistical significance depending on the comparison to the allocated alpha of 0.019 for this interim analysis.

427 **Figure 1 Kaplan-Meier Curves of Overall Survival**



428

429 The effect on PFS was also supported by analysis of PFS based on the assessment by blinded independent  
430 review. A trend favoring the cobimetinib with vemurafenib arm was observed in exploratory subgroup  
431 analyses of PFS, OS, and ORR in both BRAF V600 mutation subtypes (V600E or V600K) in the 81% of  
432 patients in this trial where BRAF V600 mutation type was determined.

433 **16 HOW SUPPLIED/STORAGE AND HANDLING**

434 COTELLIC (cobimetinib) is supplied as 20 mg film-coated tablets debossed on one side with “COB”.  
435 COTELLIC tablets are available in bottles of 63 tablets.

436 NDC 50242-717-01

437 **Storage and Stability:** Store at room temperature below 30°C (86°F).

438 **17 PATIENT COUNSELING INFORMATION**

439 See FDA-approved patient labeling (Patient Information).

440 Inform patients of the following:

441 New primary cutaneous malignancies: Advise patients to contact their health care provider immediately for  
442 change in or development of new skin lesions [*see Warnings and Precautions (5.1)*].

443 Hemorrhage: Instruct patients to contact their healthcare provider to seek immediate medical attention for  
444 signs or symptoms of unusual severe bleeding or hemorrhage [*see Warnings and Precautions (5.2)*].

445 Cardiomyopathy: Advise patients to report any history of cardiac disease and of the requirement for cardiac  
446 monitoring prior to and during COTELLIC administration. Instruct patients to immediately report any signs  
447 or symptoms of left ventricular dysfunction to their healthcare provider [*see Warnings and Precautions*  
448 *(5.3)*].

449 Serious dermatologic reactions: Instruct patients to contact their healthcare provider to immediately report  
450 severe skin changes [*see Warnings and Precautions (5.4)*].

451 Serous retinopathy and retinal vein occlusion: Instruct patients to immediately contact their healthcare  
452 provider if they experience any changes in their vision [*see Warnings and Precautions (5.5)*].

453 Hepatotoxicity: Advise patients that treatment with COTELLIC requires monitoring of their liver function.  
454 Instruct patients to report any signs or symptoms of liver dysfunction [*see Warnings and Precautions (5.6)*].

455 Rhabdomyolysis: Instruct patients to report any signs and symptoms of muscle pain or weakness to their  
456 healthcare provider [*see Warnings and Precautions (5.7)*].

457 Severe photosensitivity: Advise patients to avoid sun exposure, wear protective clothing, and use broad  
458 spectrum UVA/UVB sunscreen and lip balm (SPF  $\geq$ 30) when outdoors [*see Warnings and Precautions*  
459 *(5.8)*].

460 Embryo-fetal toxicity: Advise females of reproductive potential of the potential risk to a fetus. Advise  
461 females to contact their healthcare provider if they become pregnant, or if pregnancy is suspected, during  
462 treatment with COTELLIC [*see Warnings and Precautions (5.9), Use in Specific Populations (8.1)*].

463 Females of reproductive potential: Advise females of reproductive potential to use effective contraception  
464 during treatment with COTELLIC and for at least 2 weeks after the final dose of COTELLIC [*see Use in*  
465 *Specific Populations (8.3)*].

466 Lactation: Advise females not to breastfeed during treatment with COTELLIC and for 2 weeks after the  
467 final dose [*see Use in Specific Populations (8.2)*].

468  
469 Distributed by:  
470 **Genentech USA, Inc.**  
471 A Member of the Roche Group  
472 1 DNA Way  
473 South San Francisco, CA 94080-4990  
474

COTELLIC is a trademark of Genentech, Inc.  
©2015 Genentech, Inc.



**PATIENT INFORMATION**  
**COTELLIC™ (co-TELL-ic)**  
**(cobimetinib)**  
**tablet**

If your healthcare provider prescribes COTELLIC, also read the Medication Guide that comes with vemurafenib.

**What is COTELLIC?**

COTELLIC is a prescription medicine that is used with vemurafenib, to treat a type of skin cancer called melanoma

- that has spread to other parts of the body or cannot be removed by surgery, and
- that has a certain type of abnormal “BRAF” gene

Your healthcare provider will perform a test for the BRAF gene to make sure that COTELLIC is right for you.

- COTELLIC is not used to treat melanoma with a normal BRAF gene.

It is not known if COTELLIC is safe and effective in children under 18 years of age.

**What should I tell my healthcare provider before taking COTELLIC?**

**Before you take COTELLIC, tell your healthcare provider if you:**

- have any previous or current skin problems other than melanoma
- have any medical conditions and/or on any medications that increase your risk of bleeding
- have any heart problems
- have any eye problems
- have any liver problems
- have any muscle problems
- have any other medical conditions
- are pregnant or plan to become pregnant. COTELLIC can harm your unborn baby.
  - Patients who take COTELLIC should use effective methods of birth control during treatment with COTELLIC and for at least 2 weeks after stopping COTELLIC
  - Talk to your healthcare provider about birth control methods that may be right for you.
  - Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with COTELLIC.
- are breastfeeding or plan to breastfeed. It is not known if COTELLIC passes into your breast milk. Do not breastfeed during treatment with COTELLIC and for 2 weeks after the final dose. Talk to your healthcare provider about the best way to feed your baby during this time.

**Tell your healthcare provider about all the medicines you take**, including prescription and over-the-counter medicines, vitamins, and herbal supplements because some types of medicines will make COTELLIC more harmful or less effective.

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

**How should I take COTELLIC?**

- Take COTELLIC exactly as your healthcare provider tells you. Do not change your dose or stop taking COTELLIC unless your healthcare provider tells you to.
- COTELLIC is usually taken once daily for 21 days followed by a 7-day rest period (no drug) for a 28-day cycle.
- Take your prescribed doses of COTELLIC with or without food.
- If you miss a dose of COTELLIC or vomiting occurs, take the next dose as scheduled
- If you take too much COTELLIC, call your healthcare provider or go the nearest hospital emergency room right away.

**What should I avoid while taking COTELLIC**

Avoid sunlight while you are taking COTELLIC. COTELLIC can make your skin sensitive to sunlight. You may burn more easily and get severe sunburns. To help protect against sunburn:

- When you go outside, wear clothes that protect your skin, including your head, face, hands, arms, and legs.
- Use lip balm and a broad-spectrum sunscreen with SPF 30 or higher.

**What are the possible side effects of COTELLIC?**

**COTELLIC may cause serious side effects, including:**

- **Risk of skin cancers.** COTELLIC may cause skin cancers (cutaneous squamous cell carcinoma, keratoacanthoma, or basal cell carcinoma).

**Check your skin regularly and tell your healthcare provider right away if you have any skin changes including:**

- new wart
- skin sore or reddish bump that bleeds or does not heal
- change in size or color of a mole

Your healthcare provider should check your skin before you start taking COTELLIC, and every 2 months while taking COTELLIC. Your healthcare provider may continue to check your skin for 6 months after you stop taking COTELLIC.

- **Increased risk of bleeding.** COTELLIC may cause bleeding, including blood in the urine, rectal bleeding, unusual or excessive vaginal bleeding, bleeding of the gums, and bleeding within the brain (cerebral hemorrhage).
- Tell your healthcare provider right away if you experience any of these symptoms:
  - red or black stools that look like tar
  - abdominal pain
  - blood in the urine
  - unusual vaginal bleeding
  - headache, dizziness or feeling weak
- **Heart problems that can lead to inadequate pumping of the blood by the heart.** Your healthcare provider should perform tests before you start taking COTELLIC and during your treatment with COTELLIC to check the ability of the heart to pump blood. Signs and symptoms of a decrease in the amount of blood pumped include:
  - persistent coughing or wheezing
  - tiredness
  - shortness of breath
  - increased heart rate
  - swelling of your ankles and feet
- **Rash.** Tell your healthcare provider right away if you experience any of these symptoms:
  - a rash that covers a large area of your body, blisters, or peeling skin
- **Eye problems.** Tell your healthcare provider right away if you experience any of these symptoms during treatment with COTELLIC:
  - blurred vision
  - halos
  - distorted vision
  - any other vision changes
  - partly missing vision

Some of these eye problems may be a result of something called “serous retinopathy” (a build-up of fluid under the retina of the eye). Your healthcare provider should check your eyes if you notice any of the symptoms above.
- **Abnormal liver test or liver injury.** Your healthcare provider should perform blood tests before you start taking COTELLIC, and during treatment. Tell your healthcare provider right away if you experience any of these symptoms:
  - yellowing of your skin or the white of your eyes
  - feeling tired or weak
  - dark or brown (tea color) urine
  - loss of appetite
  - nausea or vomiting
- **Increased levels of an enzyme in the blood.** Creatine phosphokinase (CPK) is an enzyme that is primarily found in the muscle, heart, and brain. Treatment with COTELLIC may increase the level of this enzyme in your blood and be a sign of muscle damage. Your healthcare provider should perform a blood test before and during treatment. Increased blood levels of CPK can also be an indication of a serious condition caused by injury to the muscles (rhabdomyolysis). Tell your healthcare provider right away if you experience any of these symptoms:
  - muscle aches
  - dark, reddish urine
  - muscle spasms and weakness
- **Photosensitivity.** Your skin may become more sensitive to sunlight while taking COTELLIC. Tell your healthcare provider if you notice any of the following symptoms:
  - red, painful, itchy skin that is hot to touch
  - bumps or tiny papules
  - sun rash
  - thicken, dry, wrinkled skin
  - skin irritation

See “What should I avoid while taking COTELLIC” for more information on helpful tips on the management of photosensitivity

The most common side effects of COTELLIC include:

- diarrhea
- nausea
- vomiting
- sunburn or sun sensitivity
- fever

Your healthcare provider will take blood tests while you are taking COTELLIC. The most common changes to blood tests include:

- increased blood levels of liver enzymes (GGT, ALT, or AST)
- increased blood level of enzyme from muscle (creatinine phosphokinase)
- decreased blood level of phosphate, sodium or potassium
- increased blood level of liver or bone enzyme (alkaline phosphatase)
- decreased blood level of a type of white blood cell (lymphocyte)

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of COTELLIC. For more information about side effects, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Genentech at 1-888-835-2555.

**How should I store COTELLIC?**

- Store COTELLIC at room temperature below 30°C (86°F).
- Ask your healthcare provider or pharmacist how to safely throw away (dispose of) any unused or expired COTELLIC.

**Keep COTELLIC and all medicine out of the reach of children.**

**General information about COTELLIC**

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information Leaflet. Do not use COTELLIC for a condition for which it was not prescribed. Do not give COTELLIC to other people, even if they have the same symptoms that you have. It may harm them.

If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about COTELLIC that is written for health professionals.

For more information, call Genentech at 1-888-835-2555.

**What are the ingredients in COTELLIC?**

**Active ingredient:** cobimetinib fumarate

**Inactive ingredients: Tablet Core:** microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate

**Coating:** polyvinyl alcohol, titanium dioxide, polyethylene glycol 3350, talc

Distributed by: Genentech USA, Inc., A Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080-4990

COTELLIC is a trademark of Genentech, Inc.

©2015 Genentech, Inc. For more information go to [www.COTELLIC.com](http://www.COTELLIC.com) or call 1-877-436-3683.